Zacks Research Analysts Boost Earnings Estimates for ResMed

ResMed Inc. (NYSE:RMD - Free Report) - Investment analysts at Zacks Research boosted their Q1 2026 EPS estimates for ResMed in a report issued on Thursday, May 22nd. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.37 per share for the quarter, up from their previous estimate of $2.36. The consensus estimate for ResMed's current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed's Q2 2026 earnings at $2.48 EPS, Q3 2026 earnings at $2.51 EPS, FY2026 earnings at $9.83 EPS and FY2027 earnings at $10.71 EPS.

ResMed (NYSE:RMD - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same period in the previous year, the business earned $2.13 earnings per share. The firm's quarterly revenue was up 7.9% compared to the same quarter last year.

Several other research analysts have also issued reports on the stock. Citigroup upgraded shares of ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. raised their price objective on ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. Piper Sandler reduced their price objective on ResMed from $260.00 to $248.00 and set a "neutral" rating on the stock in a research note on Thursday, April 24th. Wall Street Zen cut ResMed from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th. Finally, Morgan Stanley set a $286.00 price objective on ResMed and gave the company an "overweight" rating in a research note on Tuesday, May 20th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $259.33.

ResMed Price Performance

NYSE:RMD traded up $0.16 during midday trading on Monday, hitting $244.92. The company had a trading volume of 207,082 shares, compared to its average volume of 1,038,077. ResMed has a 52-week low of $179.42 and a 52-week high of $263.05. The stock's fifty day moving average price is $229.30 and its 200-day moving average price is $234.25. The company has a market capitalization of $35.91 billion, a PE ratio of 28.92, a P/E/G ratio of 1.53 and a beta of 0.78. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13.

Institutional Trading of ResMed

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in ResMed by 1.8% in the first quarter. Vanguard Group Inc. now owns 18,493,702 shares of the medical equipment provider's stock worth $4,139,815,000 after buying an additional 320,240 shares during the period. Geode Capital Management LLC increased its stake in shares of ResMed by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider's stock valued at $899,860,000 after purchasing an additional 85,270 shares in the last quarter. Invesco Ltd. increased its stake in shares of ResMed by 32.2% during the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock valued at $531,706,000 after purchasing an additional 566,046 shares in the last quarter. Northern Trust Corp increased its stake in shares of ResMed by 2.5% during the first quarter. Northern Trust Corp now owns 1,744,541 shares of the medical equipment provider's stock valued at $390,516,000 after purchasing an additional 41,951 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of ResMed by 4.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 998,128 shares of the medical equipment provider's stock valued at $223,431,000 after purchasing an additional 41,108 shares in the last quarter. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ResMed

In other ResMed news, insider Kaushik Ghoshal sold 9,745 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $239.31, for a total value of $2,332,075.95. Following the completion of the sale, the insider now directly owns 9,725 shares in the company, valued at $2,327,289.75. This trade represents a 50.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Witte Jan De sold 2,000 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $243.47, for a total transaction of $486,940.00. Following the completion of the sale, the director now owns 5,806 shares of the company's stock, valued at $1,413,586.82. This trade represents a 25.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,949 shares of company stock worth $11,822,260. Company insiders own 0.71% of the company's stock.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be issued a dividend of $0.53 per share. The ex-dividend date is Thursday, May 8th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.87%. ResMed's dividend payout ratio is currently 23.79%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.